lupus clinical trials
Clinical Trials

Enroll in a clinical trial of an investigational medicine for lupus

If you or a loved one suffers from lupus, taking part in a clinical research study is an important step in potentially bringing new lupus drugs to patients. Without the involvement of lupus patients in clinical trials new treatments for lupus will not be possible.

Participate in a lupus clinical research study

Resolve Therapeutics is developing an investigational lupus therapy, called RSLV-132 which specifically removes molecules thought to be important in the inflammation associated with lupus without shutting down the immune system. It is hoped that by removing these molecules, inflammation will be reduced with fewer side effects.

RSLV-132 has successfully completed two clinical studies to investigate its safety and is currently enrolling patients with active lupus rash in a clinical research study. Please call us at 888-391-7570 to find out if this study is right for you.

To learn more about the clinical trial, call 888-391-7570

If you live close to one of these 12 leading rheumatology clinical study sites and would like to learn more about the clinical trial, please call the toll-free number above and a Resolve Therapeutics rep­re­sen­tative will be happy to speak with you to answer questions and provide more information.



What is Lupus?

Systemic lupus erythematosus (SLE), or lupus as it is more commonly referred to, is a chronic autoimmune disease that affects mostly women. Autoimmune diseases are those where the body’s immune system is turned against itself. The immune system, which helps the body fight infections, attacks various organs of the body in people with lupus, including the joints, skin, kidneys, and blood vessels. The most common lupus symptoms are skin rash and joint pain.

Lupus skin rash

One of the most common symptoms of lupus is a rash and the rash or rashes can take many forms. One characteristic rash can be present on the face, which is referred to as the “butterfly rash”, but rashes can also be present on the scalp, chest, arms, back, and legs. Resolve Therapeutics is conducting a clinical research study described below which is focusing on the skin rash.


Resolve Clinical Research Study

Participating in the lupus study will involve a total of 13 visits over the course of 6 months; each visit will take approximately 1-2 hours. Lupus patients participating in the study will undergo study related physical examinations, be evaluated by an experienced rheumatologist at each visit and have blood drawn for safety and to measure various markers of inflammation. These markers of inflammation may suggest how the drug is performing in decreasing inflammation. Most patients in the study will receive 13 infusions of RSLV132 at two week intervals over the course of 6 months. One of the primary goals of the study is to monitor the improvement in skin rash to determine if the drug is able to improve the skin disease. All study-related examinations, blood tests, treatments and evaluations are paid for by the study and there is no cost to the patient. A stipend may be provided to cover time and travel expenses.


Am I eligible for this study?

To be eligible for the study you must:
  • Be diagnosed with systemic lupus
  • Have a rash on more than one area of your body
You cannot:
  • Have participated in another clinical study within 6 months.
  • Be on more than 10 mg/day of Prednisone
  • Be on Benlysta
  • Be on certain immunosuppressant drugs

Study Sites

(Click on your state to see locations.)

California
El Cajon
Los Alamitos
Los Angeles

Florida
Clearwater
Naples

New York
Great Neck

North Carolina
Charlotte
Winston-Salem

Texas
Dallas

To learn more about the clinical trial, call 888-391-7570

If you live close to one of these 12 leading rheumatology clinical study sites and would like to learn more about the clinical trial, please call the toll-free number above and a Resolve Therapeutics rep­re­sen­tative will be happy to speak with you to answer questions and provide more information.